MI HB5950

Expands the newborn screening quality assurance advisory committee to clarify it consists of 10 members representing various healthcare organizations, medical societies, and the general public.

Modifies the advisory committee's annual review process to reference both section 5431 and the new section 5431a for required newborn screening tests.

Adds requirement for advisory committee to conduct financial review of recommended changes to the screening test list, with any fee increases limited to the net cost difference between added and removed tests.

Establishes a new section 5431a requiring testing of newborns for five lysosomal storage disorders: Krabbe, Pompe, Gaucher, Fabry, and Niemann-Pick, to begin once specified FDA and CDC requirements are met.

Creates a process for the department to issue an order establishing the implementation date for the new lysosomal storage disorder tests within 6 months of determining all regulatory and quality assurance requirements have been satisfied.